27853635|t|Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
27853635|a|Programmed Death 1 (PD-1) and T cell Ig and mucin domain-3 protein (Tim-3) are immune checkpoint receptors highly expressed on tumor infiltrating T lymphocytes (TIL). PD-1 inhibits T cell activation and type-1 T cell responses, while Tim-3 is proposed to mark more extensively exhausted cells, although the mechanisms underlying Tim-3 function are not clear. Trials of anti-PD-1 therapy have identified a large subset of non-responder patients, likely due to expression of alternative checkpoint molecules like Tim-3. We investigated the phenotypic and functional characteristics of T cells with differential expression of PD-1 (high/low) and Tim-3 (positive / negative), using TIL directly isolated from head and neck squamous cell carcinomas (HNSCC). Unexpectedly, we found that expression of Tim-3 alone does not necessarily mark TIL as dysfunctional / exhausted. In Tim-3-TIL, PD-1 levels correlate with T cell dysfunction, with a PD-1(low/intermed) phenotype identifying recently activated and still functional cells, whereas PD-1(hi)Tim-3(-) T cells are actually exhausted. Nonetheless, PD-1(intermed) cells are still potently suppressed by PD-L1. PD-1 expression was associated with reduced phosphorylation of ribosomal protein S6 (pS6), whereas Tim-3 expression was associated with increased pS6. Using a novel mouse model for inducible Tim-3 expression, we confirmed that expression of Tim-3 does not necessarily render T cells refractory to further activation. These results suggest the existence of PD-1 and Tim-3 crosstalk in regulating antitumor T cell responses, with important implications for anti-PD-1 immunotherapy.
27853635	0	35	Tumor-infiltrating Tim-3(+) T cells	T025	C0039194
27853635	36	47	proliferate	T043	C1155046
27853635	67	71	PD-1	T116,T129,T192	C2986635
27853635	75	87	co-expressed	T045	C0597360
27853635	102	115	intracellular	T082	C0178719
27853635	116	126	cross talk	T043	C0007613
27853635	127	145	Programmed Death 1	T116,T129,T192	C2986635
27853635	147	151	PD-1	T116,T129,T192	C2986635
27853635	157	193	T cell Ig and mucin domain-3 protein	T116	C3537335
27853635	195	200	Tim-3	T116	C3537335
27853635	206	233	immune checkpoint receptors	T116,T192	C0597357
27853635	241	250	expressed	T045	C0597360
27853635	254	286	tumor infiltrating T lymphocytes	T025	C0039194
27853635	288	291	TIL	T025	C0039194
27853635	294	298	PD-1	T116,T129,T192	C2986635
27853635	299	307	inhibits	T052	C3463820
27853635	308	325	T cell activation	T043	C1155065
27853635	330	353	type-1 T cell responses	T043	C0007613
27853635	361	366	Tim-3	T116	C3537335
27853635	404	413	exhausted	T184	C0392674
27853635	414	419	cells	T025	C0007634
27853635	434	444	mechanisms	T044	C3537153
27853635	456	461	Tim-3	T116	C3537335
27853635	486	492	Trials	T062	C0681815
27853635	496	513	anti-PD-1 therapy	T061	C0021083
27853635	548	570	non-responder patients	T101	C0030705
27853635	586	596	expression	T045	C0597360
27853635	638	643	Tim-3	T116	C3537335
27853635	665	675	phenotypic	T032	C1318444
27853635	680	690	functional	T043	C0007613
27853635	710	717	T cells	T025	C0039194
27853635	736	746	expression	T045	C1171362
27853635	750	754	PD-1	T116,T129,T192	C2986635
27853635	770	775	Tim-3	T116	C3537335
27853635	777	785	positive	T033	C1446409
27853635	788	796	negative	T033	C0205160
27853635	805	808	TIL	T025	C0039194
27853635	832	870	head and neck squamous cell carcinomas	T191	C1168401
27853635	872	877	HNSCC	T191	C1168401
27853635	908	918	expression	T045	C0597360
27853635	922	927	Tim-3	T116	C3537335
27853635	960	963	TIL	T025	C0039194
27853635	967	980	dysfunctional	T077	C3887504
27853635	983	992	exhausted	T184	C0392674
27853635	997	1006	Tim-3-TIL	T025	C0039194
27853635	1008	1012	PD-1	T116,T129,T192	C2986635
27853635	1035	1041	T cell	T025	C0039194
27853635	1042	1053	dysfunction	T077	C3887504
27853635	1062	1090	PD-1(low/intermed) phenotype	T032	C1318444
27853635	1112	1121	activated	T052	C1879547
27853635	1132	1142	functional	T169	C0205245
27853635	1143	1148	cells	T025	C0007634
27853635	1158	1182	PD-1(hi)Tim-3(-) T cells	T025	C0039194
27853635	1196	1205	exhausted	T184	C0392674
27853635	1220	1240	PD-1(intermed) cells	T025	C0007634
27853635	1274	1279	PD-L1	T116,T129,T192	C2986635
27853635	1281	1285	PD-1	T116,T129,T192	C2986635
27853635	1286	1296	expression	T045	C0597360
27853635	1301	1316	associated with	T080	C0332281
27853635	1325	1340	phosphorylation	T044	C1158886
27853635	1344	1364	ribosomal protein S6	T116,T123	C0073336
27853635	1366	1369	pS6	T116,T123	C0073336
27853635	1380	1385	Tim-3	T116	C3537335
27853635	1386	1396	expression	T045	C0597360
27853635	1401	1416	associated with	T080	C0332281
27853635	1427	1430	pS6	T116,T123	C0073336
27853635	1446	1457	mouse model	T050	C2986594
27853635	1472	1477	Tim-3	T116,T192	C3252613
27853635	1478	1488	expression	T045	C0597360
27853635	1508	1518	expression	T045	C0597360
27853635	1522	1527	Tim-3	T116,T192	C3252613
27853635	1556	1563	T cells	T025	C1522131
27853635	1586	1596	activation	T043	C1326120
27853635	1637	1641	PD-1	T116,T129,T192	C2986635
27853635	1646	1651	Tim-3	T116	C3537335
27853635	1652	1661	crosstalk	T043	C0007613
27853635	1676	1685	antitumor	T042	C1516031
27853635	1686	1702	T cell responses	T043	C0007613
27853635	1736	1759	anti-PD-1 immunotherapy	T061	C0021083